Various preclinical studies and ongoing clinical trials aimed to evaluate the efficiency of CD38 antibodies in hematological malignancies such as NK/T cell lymphoma and acute lymphoblastic leukemia [27, 28]. The gene discussed is CD38; the disease is acute lymphoblastic leukemia.